Murray Stewart
Director/Board Member at X4 PHARMACEUTICALS, INC.
Net worth: 169 317 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Paula Ragan | M | 54 | 10 years | |
| Paul Carter | M | 63 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 14 years |
| Mark Dipaolo | M | 53 | 3 years | |
| Sandipkumar S. Kapadia | M | 54 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 years |
| Stephen P. Squinto | M | 67 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 years |
| Chahra Khaoua Epouse Louafi | F | 53 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 years |
| Odysseas Kostas | M | 49 | 1 years | |
| Johannes G. C. P. Schikan | M | 66 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 years |
| Phil Thomson | M | - | 13 years | |
| Luca Santarelli | M | 55 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 years |
| Emma Walmsley | F | 55 | 14 years | |
| Thomas Woiwode | M | 52 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 years |
| Adam Mostafa | M | 44 | 6 years | |
| Mary DiBiase | M | 63 | 7 years | |
| David Connolly | M | - | 5 years | |
| Jesse Goodman | M | 72 | 8 years | |
| Keith Horn | M | 66 | 1 years | |
| Patrice Bonfiglio | F | 40 | 1 years | |
| Tony Wood | M | - | 7 years | |
| Diane Sullivan | F | 62 | 1 years | |
| Françoise de Craecker | F | 62 | 3 years | |
| Michael Wyzga | M | 69 | 6 years | |
| Stuart Arbuckle | M | 58 | 5 years | |
| Paul Cohen | M | 49 | 1 years | |
| Jennifer Good | F | 59 | 5 years | |
| David McGirr | M | 69 | 7 years | |
| Camille Bedrosian | M | 71 | 4 years | |
| Lynn Tetrault | F | 61 | 4 years | |
| Louis Sterling | M | 45 | 1 years | |
| Bill Aliski | M | 75 | 5 years | |
| Alison Lawton | F | 62 | 4 years | |
| Gary Bridger | M | 61 | 6 years | |
| Timothy Woodthorpe | M | - | 24 years | |
| Pamela Cramer | F | 50 | 3 years | |
| Jim Flaherty | M | - | 5 years | |
| Frannie DeFranco | F | - | 14 years | |
| Anita Kidgell | F | - | 16 years | |
| Sally Jackson | F | - | 23 years | |
| Elisabeth Crönert-Bendell | M | - | 3 years | |
| Joseph Shulman | M | 49 | 4 years | |
| Mark Baldry | M | 60 | 2 years | |
| Diana Conrad | F | - | 8 years | |
| Yann Mazabraud | M | 51 | 4 years | |
| R. Woods | M | 57 | 1 years | |
| Christophe Arbet-Engels | M | - | 1 years | |
| María Cristina de Luna Basagoiti | F | - | 14 years | |
| Luke Miels | M | - | 7 years | |
| Art Taveras | M | 60 | 4 years | |
| Victoria Whyte | F | - | 15 years | |
| Christian Meyer | M | 56 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | - |
| Jennifer Chien | F | 49 | 4 years | |
| Barbara Beirer | M | - |
Vivli Center For Global Clinical Research Data
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Keith Gottesdiener | M | 70 | 9 years | |
| René Russo | M | 49 | 6 years | |
| Gregory Perry | M | 63 | 1 years | |
| Andrew Witty | M | 59 | - | |
| Moncef Slaoui | M | 64 | 11 years | |
| Philip Hampton | M | 70 | 4 years | |
| Thomas Mount | M | - | 7 years | |
| Michael Dennis Price | M | 66 | 3 years | |
| Saul Charles Klein | M | 53 | 2 years | |
| Kevin Kotler | M | 53 | 2 years | |
| Roy Anderson | M | 76 | 11 years | |
| William Louv | M | - | 21 years | |
| Patrick J. T. Vallance | M | 64 | - | |
| Sarah Elton-Farr | F | - | 4 years | |
| Peter Traber | M | 69 | 3 years | |
| Anjali Bansal | F | 53 | 6 years | |
| Alfonso Zulueta | M | 61 | 1 years | |
| Balbir Kelly Bisla | F | - | 4 years | |
| Derek Meisner | M | 53 | 3 years | |
| Wouter Joustra | M | 35 | 1 years | |
| Ravi Rao | M | 55 | 7 years | |
| Patrick Malloy | M | - | - | |
| Robert Carr | M | - | 26 years | |
| Adam Berger | M | - | 1 years | |
| Scott Applebaum | M | 57 | - | |
| Vindi Banga | M | 69 | 7 years | |
| Urs Rohner | M | 65 | 9 years | |
| Christopher Gent | M | 75 | 11 years | |
| Maxine Gowen | M | 66 | 13 years | |
| Judy Lewent | F | 75 | 10 years | |
| H. Culp | M | 60 | 9 years | |
| Laurie Glimcher | M | 72 | 5 years | |
| Jan van Heek | M | 75 | 13 years | |
| Deryck Charles Maughan | M | 76 | 12 years | |
| Ian Maurice Gray Prosser | M | 81 | 9 years | |
| Robert Wilson | M | 81 | 11 years | |
| Richard Sykes | M | 79 | 7 years | |
| Dame Cox | F | 64 | 6 years | |
| John David Coombe | M | 79 | 5 years | |
| Michèle Barzach | M | - | 7 years | |
| Crispin Davis | M | 75 | 10 years | |
| Per Wold-Olsen | M | 76 | 1 years | |
| Stacey Cartwright | F | 60 | 5 years | |
| Gerardus Johannes Wijers | M | 74 | 3 years | |
| Todd Foley | M | 52 | 7 years | |
| Simon Dingemans | M | 61 | 8 years | |
| Julian Heslop | M | 70 | 13 years | |
| Geraldine Murphy | F | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 46 | 46.00% |
| United States | 29 | 29.00% |
| Ireland | 12 | 12.00% |
| Switzerland | 11 | 11.00% |
| Canada | 4 | 4.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Murray Stewart
- Personal Network
